MedTrace Logo

Dose-Finding Study of E7070 in Combination With Irinotecan

NCT00060567 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2023-06-18

No results posted yet for this study

Summary

E7070 and irinotecan will be administered to patients with GI tract, pancreatic or lung tumors on Days 1 and 8 of a 21-day cycle, or Days 1 and 15 of a 28-day cycle according to one of two E7070 dose escalation schemes.

Conditions

Interventions

DRUG

E7070 + irinotecan combination

Escalating doses starting from 125 mg/m2 irinotecan plus 250 mg/m2 E7070 combination.

DRUG

Irinotecan + E7070 combination

Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.

DRUG

Irinotecan + E7070 combination

Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.

Sponsors & Collaborators

  • Eisai Inc.

    lead INDUSTRY

Principal Investigators

  • Eisai Medical Services · Eisai Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00060567 on ClinicalTrials.gov